• Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page

Phathom

Quote




anonymous said:
You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
Click to expand...

anonymous said:
You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
Click to expand...
who is the idiot now?
 








anonymous said:
You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
Click to expand...
You clearly aren’t qualified to discuss stock. And didn’t your mother teach you not to call people names ?
Karma is a bitch.
 




























If there is no GAIN for EE an at-risk generic will launch mid 2026. Stock market knows, Takeda has given full vonoprazan dossiers to a bunch of Indian companies as licenses for India so knowledge is transferred.
 




anonymous said:
If there is no GAIN for EE an at-risk generic will launch mid 2026. Stock market knows, Takeda has given full vonoprazan dossiers to a bunch of Indian companies as licenses for India so knowledge is transferred.
Click to expand...
That’s not true bud! Good try. Takeda would get sued if that were the case. Do I think this company is ran by a bunch of fucking idiots? Absolutely, but their not that dumb to let takeka sale the knowledge behind the compound. Now with that said we all came here to make money off a sale in stock and it will never sale until the FDA changes the language in the orange book. These other companies that were about to launch their PCAB’s are freaking out. Their stock is shit too. Once the language is change it will go back up. Maybe not to what it was but it will.
 




ChatGPT:

Takeda Pharmaceutical Company has entered into non-exclusive patent licensing agreements with several Indian pharmaceutical companies to commercialize vonoprazan in India. These companies include:

  • Cipla Limited: Announced on June 20, 2024, Cipla signed a non-exclusive patent license agreement with Takeda to commercialize vonoprazan for treating acid-related illnesses in India.
    Cipla

  • Sun Pharmaceutical Industries Limited: On June 21, 2024, Sun Pharma entered into a similar agreement with Takeda to market vonoprazan tablets under the brand name "Voltapraz" in India.
    Sun Pharmaceutical Industries

  • Lupin Limited: On September 18, 2024, Lupin announced a non-exclusive patent license agreement with Takeda to commercialize vonoprazan tablets in India under the brand name "Lupivon."
    Lupin

  • Alkem Laboratories: In September 2024, Alkem signed a non-exclusive patent license agreement with Takeda to commercialize vonoprazan in India under the brand name "Vonzai."
    Express Pharma

  • Mankind Pharma: In June 2024, Mankind Pharma entered into a non-exclusive patent license agreement with Takeda to commercialize vonoprazan in the Indian market.
    Express Pharma
These agreements allow each company to market vonoprazan in India under their respective brand names, expanding the availability of this gastrointestinal treatment in the Indian market.
 




anonymous said:
ChatGPT:

Takeda Pharmaceutical Company has entered into non-exclusive patent licensing agreements with several Indian pharmaceutical companies to commercialize vonoprazan in India. These companies include:

  • Cipla Limited: Announced on June 20, 2024, Cipla signed a non-exclusive patent license agreement with Takeda to commercialize vonoprazan for treating acid-related illnesses in India.
    Cipla

  • Sun Pharmaceutical Industries Limited: On June 21, 2024, Sun Pharma entered into a similar agreement with Takeda to market vonoprazan tablets under the brand name "Voltapraz" in India.
    Sun Pharmaceutical Industries

  • Lupin Limited: On September 18, 2024, Lupin announced a non-exclusive patent license agreement with Takeda to commercialize vonoprazan tablets in India under the brand name "Lupivon."
    Lupin

  • Alkem Laboratories: In September 2024, Alkem signed a non-exclusive patent license agreement with Takeda to commercialize vonoprazan in India under the brand name "Vonzai."
    Express Pharma

  • Mankind Pharma: In June 2024, Mankind Pharma entered into a non-exclusive patent license agreement with Takeda to commercialize vonoprazan in the Indian market.
    Express Pharma
These agreements allow each company to market vonoprazan in India under their respective brand names, expanding the availability of this gastrointestinal treatment in the Indian market.
Click to expand...
I get that but they can’t sale it in the US, Canada and Europe. Now they might try but they would again get sued. Let’s face it this drug not even touching 100 million for long time. No company wants to sale a generic making 16 million a quarter.
 








anonymous said:
I get that but they can’t sale it in the US, Canada and Europe. Now they might try but they would again get sued. Let’s face it this drug not even touching 100 million for long time. No company wants to sale a generic making 16 million a quarter.
Click to expand...
But single molecule vonoprazan in the US is not classified in the orange book under infectious disease, which allots 5 extra years, such as in the case of dual and tripple pack which both fall under this title granted by the FDA. Voquezna 10 & 20 mg, if not classified as such, so Vonoprazan loses exclusivity in 2026. Hence the options of 1) a peoples polling 2) litigation 3) do nothing. Per Phathom
 




anonymous said:
I get that but they can’t sale it in the US, Canada and Europe. Now they might try but they would again get sued. Let’s face it this drug not even touching 100 million for long time. No company wants to sale a generic making 16 million a quarter.
Click to expand...
Why do you always use the word “sale” when the proper word is “sell?” Multiple posts and you have been exposed.
 








anonymous said:
You're very wrong. Either this is the ironwood idiot or one of my phellow PIP clowns
Click to expand...
Go ahead and show your proof.
Direct quote from the Orange Book is never wrong buddy .

“Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not.
FDA Orange Book Vonoprazan Exclusivity expiration dates:
  • November 1, 2026 - NEW PRODUCT
  • May 3, 2027 - NEW CHEMICAL ENTITY
  • July 17, 2027 - USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS”
 




anonymous said:
Go ahead and show your proof.
Direct quote from the Orange Book is never wrong buddy .

“Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not.
FDA Orange Book Vonoprazan Exclusivity expiration dates:
  • November 1, 2026 - NEW PRODUCT
  • May 3, 2027 - NEW CHEMICAL ENTITY
  • July 17, 2027 - USE OF VONOPRAZAN FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE IN ADULTS”
Click to expand...
How's that stock doing snowflakes?
 




Top Bottom
Back
Quote